ABSTRACT
INTRODUCTION: Guillain-Barré syndrome (GBS) is an acute-onset, immune-mediated disease of the peripheral nervous system. It may be classified into 2 main subtypes: demyelinating (AIDP) and axonal (AMAN). This study aims to analyse the mechanisms of axonal damage in the early stages of GBS (within 10 days of onset). DEVELOPMENT: We analysed histological, electrophysiological, and imaging findings from patients with AIDP and AMAN, and compared them to those of an animal model of myelin P2 protein-induced experimental allergic neuritis. Inflammatory oedema of the spinal nerve roots and spinal nerves is the initial lesion in GBS. The spinal nerves of patients with fatal AIDP may show ischaemic lesions in the endoneurium, which suggests that endoneurial inflammation may increase endoneurial fluid pressure, reducing transperineurial blood flow, potentially leading to conduction failure and eventually to axonal degeneration. In patients with AMAN associated with anti-ganglioside antibodies, nerve conduction block secondary to nodal sodium channel dysfunction may affect the proximal, intermediate, and distal nerve trunks. In addition to the mechanisms involved in AIDP, active axonal degeneration in AMAN may be associated with nodal axolemma disruption caused by anti-ganglioside antibodies. CONCLUSION: Inflammatory oedema of the proximal nerve trunks can be observed in early stages of GBS, and it may cause nerve conduction failure and active axonal degeneration.
Subject(s)
Guillain-Barre Syndrome , Amantadine , Animals , Axons/pathology , Neural Conduction/physiology , Peripheral Nerves/pathologyABSTRACT
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease affecting motor neurons. Although a small proportion of ALS cases are familial in origin and linked to mutations in specific genes, most cases are sporadic and have a multifactorial aetiology. Some recent studies have increased our knowledge of ALS pathogenesis and raised the question of whether this disorder is a proteinopathy, a ribonucleopathy, an axonopathy, or a disease related to the neuronal microenvironment. DEVELOPMENT: This article presents a review of ALS pathogenesis. To this end, we have reviewed published articles describing either ALS patients or ALS animal models and we discuss how the main cellular pathways (gene processing, protein metabolism, oxidative stress, axonal transport, relationship with neuronal microenvironment) may be involved in motor neurons degeneration. CONCLUSIONS: ALS pathogenesis has not been fully elucidated. Recent studies suggest that although initial triggers may differ among patients, the final motor neurons degeneration mechanisms are similar in most patients once the disease is fully established.
Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Motor Neurons/pathology , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Animals , Disease Models, Animal , HumansABSTRACT
INTRODUCTION: Guillain-Barré syndrome (GBS) is an acute-onset, immune-mediated disease of the peripheral nervous system. It may be classified into 2 main subtypes: demyelinating (AIDP) and axonal (AMAN). This study aims to analyse the mechanisms of axonal damage in the early stages of GBS (within 10days of onset). DEVELOPMENT: We analysed histological, electrophysiological, and imaging findings from patients with AIDP and AMAN, and compared them to those of an animal model of myelin P2 protein-induced experimental allergic neuritis. Inflammatory oedema of the spinal nerve roots and spinal nerves is the initial lesion in GBS. The spinal nerves of patients with fatal AIDP may show ischaemic lesions in the endoneurium, which suggests that endoneurial inflammation may increase endoneurial fluid pressure, reducing transperineurial blood flow, potentially leading to conduction failure and eventually to axonal degeneration. In patients with AMAN associated with anti-ganglioside antibodies, nerve conduction block secondary to nodal sodium channel dysfunction may affect the proximal, intermediate, and distal nerve trunks. In addition to the mechanisms involved in AIDP, active axonal degeneration in AMAN may be associated with nodal axolemma disruption caused by anti-ganglioside antibodies. CONCLUSION: Inflammatory oedema of the proximal nerve trunks can be observed in early stages of GBS, and it may cause nerve conduction failure and active axonal degeneration.
ABSTRACT
Neurologic manifestations are found in 5-15 % of patients with sarcoidosis. This granulomatous disease may affect any part of the peripheral or the central nervous system, being potentially severe and difficult to treat. Corticosteroids are the cornerstone of therapy in sarcoidosis. However, some patients become resistant or experience side effects to corticosteroids. In these patients, second line therapies including immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate, cyclophosphamide and leflunomide have been used. Anti-TNF-α drugs have been proposed as a therapeutic option for those who are refractory to immunosuppressive drugs or initially in cases of severe sarcoidosis. We report on 5 patients with neurosarcoidosis treated with anti-TNF-α drugs in our center. A literature review of patients with neurosarcoidosis treated with anti-TNF-α drugs was conducted. In our series successful response to anti-TNF-α therapy was achieved. However, the high frequency of relapses following anti-TNF-α discontinuation makes necessary a close follow-up of these patients when the biologic agent is stopped.
Subject(s)
Central Nervous System Diseases , Immunosuppressive Agents , Sarcoidosis , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Adult , Aged , Biopsy , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/immunology , Central Nervous System Diseases/physiopathology , Drug Resistance , Female , Granuloma/immunology , Granuloma/pathology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/classification , Lymph Nodes/pathology , Male , Middle Aged , Sarcoidosis/diagnosis , Sarcoidosis/drug therapy , Sarcoidosis/immunology , Sarcoidosis/physiopathology , Secondary Prevention , Treatment Outcome , Tumor Necrosis Factor-alpha/immunologyABSTRACT
BACKGROUND AND PURPOSE: Common genetic variants (rs5848 and rs646776) have been reported as regulators of blood progranulin (GRN) levels in healthy individuals. METHODS: To assess the influence of rs5848 and rs646776 polymorphisms in both serum GRN level and risk for common neurodegenerative diseases, we studied 304 patients with Parkinson's disease (PD), 217 individuals with Alzheimer's disease, 131 subjects with mild cognitive impairment, and 126 controls. RESULTS: The mean concentration of GRN in the serum of patients with PD (319.6 ng/ml) was significantly lower than that of controls (371.5 ng/ml; P = 0.009), whereas there were no significant differences between other groups. Rs646776 minor allele carriers had lower serum GRN levels in each of the four subgroups. There was no correlation between rs5848 genotypes and serum GRN concentrations. Genotype frequencies of both polymorphisms did not differ between groups. CONCLUSION: Reduced circulating GRN levels might be associated with PD risk by pathogenic factors different from rs5848 and rs646776 polymorphisms.
Subject(s)
Intercellular Signaling Peptides and Proteins/blood , Parkinson Disease/blood , Aged , Aged, 80 and over , Female , Genetic Predisposition to Disease , Genotype , Humans , Intercellular Signaling Peptides and Proteins/genetics , Male , Parkinson Disease/genetics , Polymorphism, Single Nucleotide , ProgranulinsSubject(s)
Cerebral Arterial Diseases/etiology , Guillain-Barre Syndrome/diagnosis , Posterior Cerebral Artery/diagnostic imaging , Subarachnoid Hemorrhage/etiology , Acute Disease , Cerebral Arterial Diseases/diagnostic imaging , Constriction, Pathologic/diagnostic imaging , Female , Guillain-Barre Syndrome/complications , Humans , Middle Aged , Subarachnoid Hemorrhage/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Aside from APOE, the genetic factors that influence the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) remain largely unknown. We assessed whether a genetic risk score (GRS), based on eight non-APOE genetic variants previously associated with AD risk in genome-wide association studies, is associated with either risk of conversion or with rapid progression from MCI to AD. Among 288 subjects with MCI, follow-up (mean 26.3 months) identified 118 MCI-converters to AD and 170 MCI-nonconverters. We genotyped ABCA7 rs3764650, BIN1 rs744373, CD2AP rs9296559, CLU rs1113600, CR1 rs1408077, MS4A4E rs670139, MS4A6A rs610932, and PICALM rs3851179. For each subject we calculated a cumulative GRS, defined as the number of risk alleles (range 0-16) with each allele weighted by the AD risk odds ratio. GRS was not associated with risk of conversion from MCI to AD. However, MCI-converters to AD harboring six or more risk alleles (second and third GRS tertiles) progressed twofold more rapidly to AD when compared with those with less than six risk alleles (first GRS tertile). Our GRS is a first step toward development of prediction models for conversion from MCI to AD that incorporate aggregate genetic factors.
Subject(s)
Alzheimer Disease/genetics , Cognitive Dysfunction/genetics , Genetic Predisposition to Disease , ATP-Binding Cassette Transporters/genetics , Adaptor Proteins, Signal Transducing/genetics , Aged , Aged, 80 and over , Alzheimer Disease/complications , Apolipoproteins E/genetics , Clusterin/genetics , Cognitive Dysfunction/complications , Disease Progression , Female , Follow-Up Studies , Gene Frequency , Genetic Association Studies , Genome-Wide Association Study , Genotype , Humans , Male , Membrane Proteins/genetics , Middle Aged , Monomeric Clathrin Assembly Proteins/genetics , Receptors, Complement 3b/genetics , RiskABSTRACT
INTRODUCTION: Charcot-Marie-Tooth disease (CMT) is the most frequent form of inherited neuropathy. In accordance with the inheritance pattern and degree of slowing of motor conduction velocity (MCV) of the median nerve, CMT encompasses five main forms: CMT1 (autosomal dominant [AD] or X-linked transmission and MCV < 38 m/s); CMT2 (AD or X-linked transmission and MCV > 38 m/s); CMT4 (autosomal recessive [AR] and severe slowing of MCV); AR-CMT2 (AR transmission and MCV > 38 m/s); and DI-CMT (intermediate form with AD transmission and MCV between 30 and 40 m/s). In spite of its stereotyped semiological repertoire (basically, symptoms and signs of sensory-motor polyneuropathy and pes cavus), CMT seems to be one of the most complex hereditary neurodegenerative syndromes, 31 causative genes having been cloned. DEVELOPMENT: This paper is aimed at performing a nosological review of the disease, emphasising the guidelines for its molecular diagnosis. Genetic epidemiological studies and genotypes reported in Spanish patients are revised. CONCLUSIONS: In the great majority of CMT cases, mutations involve a reduced number of genes, namely: for CMT1, PMP22, GJB1 and MPZ; for CMT2, MFN2 and GJB1; for CMT4, GDAP1, and NDRG1, HK1 and SH3TC2 (gypsies); for AR-CMT2, GDAP1; and for DI-CMT, GJB1 and MPZ. Given their low prevalence, mutations in other pathogenic genes should be investigated after discarding the previous ones. There is no place for the indiscriminate use of diagnostic CMT genetic panels.
Subject(s)
Charcot-Marie-Tooth Disease/diagnosis , Charcot-Marie-Tooth Disease/genetics , Genetic Markers , Guidelines as Topic , Humans , Molecular Epidemiology , Mutation/genetics , Mutation/physiologyABSTRACT
OBJECTIVE: To obtain quantitative data on the progression of the most common spinocerebellar ataxias (SCAs) and identify factors that influence their progression, we initiated the EUROSCA natural history study, a multicentric longitudinal cohort study of 526 patients with SCA1, SCA2, SCA3, or SCA6. We report the results of the 1- and 2-year follow-up visits. METHODS: As the primary outcome measure we used the Scale for the Assessment and Rating of Ataxia (SARA, 0-40), and as a secondary measure the Inventory of Non-Ataxia Symptoms (INAS, 0-16) count. RESULTS: The annual increase of the SARA score was greatest in SCA1 (2.18 ± 0.17, mean ± SE) followed by SCA3 (1.61 ± 0.12) and SCA2 (1.40 ± 0.11). SARA progression in SCA6 was slowest and nonlinear (first year: 0.35 ± 0.34, second year: 1.44 ± 0.34). Analysis of the INAS count yielded similar results. Larger expanded repeats and earlier age at onset were associated with faster SARA progression in SCA1 and SCA2. In SCA1, repeat length of the expanded allele had a similar effect on INAS progression. In SCA3, SARA progression was influenced by the disease duration at inclusion, and INAS progression was faster in females. CONCLUSIONS: Our study gives a comprehensive quantitative account of disease progression in SCA1, SCA2, SCA3, and SCA6 and identifies factors that specifically affect disease progression.
Subject(s)
Disease Progression , Machado-Joseph Disease/classification , Machado-Joseph Disease/diagnosis , Spinocerebellar Ataxias/classification , Spinocerebellar Ataxias/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Humans , Longitudinal Studies , Machado-Joseph Disease/epidemiology , Male , Middle Aged , Prospective Studies , Retrospective Studies , Spinocerebellar Ataxias/epidemiology , Young AdultABSTRACT
BACKGROUND: The spinocerebellar ataxias (SCA) are a group of genetic neurodegenerative diseases, clinically and pathologically heterogeneous, characterized by slowly progressive cerebellar ataxia. OBJECTIVE: To identify the neural pathways affected neurophysiologically, correlate the findings with the size of CAG expansion and determine the contribution of neurophysiological studies in the differential diagnosis of the two most prevalent genotypes in Spain, SCA2 and SCA3. METHOD: We examined 10 SCA2 and 12 SCA3 patients by electromyography, electroneurography motor and sensory, multimodal evoked potentials, transcranial magnetic stimulation, blink reflex and masseter reflex. In the statistical analysis linear regression studies were performed, and the, Spearman correlation coefficient and nonparametric test U of Mann-Whitney calculated. RESULTS: We detected the presence of a predominantly sensory neuropathy in most SCA2 patients and in a minority of SCA3 patients; the central somatosensory pathway showed significant defects in both populations. We recorded a high incidence of brain-stem electrophysiological abnormalities in SCA2 patients; in particular, the masseter reflex was abnormal in all SCA2 patients, remaining intact in all SCA3 patients. The study of cortico-spinal pathway showed a greater percentage of abnormalities in both populations than in previous studies. CONCLUSION: SCA2 is a model of sensory neuronopathy with central and peripheral axonopathy. Studies of brain-stem pathways show a higher incidence of abnormalities in SCA2 patients. SCA3 patients show major changes in the central somatosensory pathway with relative normality of the electroneurography. The masseter reflex was the most useful test in the differential diagnosis between both genotypes.
Subject(s)
Machado-Joseph Disease/physiopathology , Nervous System Physiological Phenomena , Spinocerebellar Ataxias/physiopathology , Adult , Aged , Diagnosis, Differential , Female , Genotype , Humans , Machado-Joseph Disease/diagnosis , Machado-Joseph Disease/genetics , Male , Middle Aged , Spinocerebellar Ataxias/diagnosis , Spinocerebellar Ataxias/geneticsABSTRACT
BACKGROUND: Oxidative stress is a central factor in the pathogenesis of Parkinson's disease (PD). Heme oxygenase-1 (HO-1) is an antioxidant protein expressed in response to oxidative challenge, and its expression levels are inversely correlated with glycogen synthase kinase-3beta (GSK3beta) activity. Underexpression of HO-1 in concert with an upregulation of GSK3beta would result in a less effective antioxidant response and might increase the risk of PD. METHODS: We examined two functional polymorphism in the promoter regions of HO-1 (-413, rs2071746) and GSK3beta (-157, rs6438552) in a group of 251 Spanish patients with PD and 234 controls. RESULTS: Subjects carrying both the HO-1 (-413, rs2071746) TT genotype and the GSK3beta (-157, rs6438552) TT genotype had a four times higher risk of developing PD than subjects without these genotypes (adjusted by age and sex OR = 4.12; 95% CI = 1.45-11.71; Bonferroni corrected P = 0.024). CONCLUSIONS: Considering synergistic effects between polymorphisms in oxidative stress-related genes may help in determining the risk profile for PD.
Subject(s)
Genetic Predisposition to Disease/genetics , Glycogen Synthase Kinase 3/genetics , Heme Oxygenase-1/genetics , Oxidative Stress/genetics , Parkinson Disease/enzymology , Parkinson Disease/genetics , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Gene Frequency/genetics , Genotype , Glycogen Synthase Kinase 3 beta , Humans , Male , Middle Aged , Polymorphism, Genetic/genetics , Promoter Regions, Genetic/genetics , Risk AssessmentABSTRACT
OBJECTIVE: Oxidative stress is implicated in Parkinson's disease (PD) and Alzheimer's disease (AD), and heme oxygenase-1 (HO-1) is a potent antioxidant overexpressed in PD substantia nigra and AD cerebral cortex and hippocampus, indicating a possible up-regulation of antioxidant defenses in both neurodegenerative diseases. The role of HO-1 in peripheral blood of PD and AD patients remains unresolved. METHODS: We measured serum HO-1 levels in 107 patients with PD, 105 patients with AD, 104 controls for PD and 120 controls for AD. RESULTS: The median serum concentration of HO-1 was significantly higher in PD patients (2.04 ng/ml) compared with that of PD controls (1.69 ng/ml, P = 0.016), with PD patients predominating over controls in the upper tertile of serum HO-1 levels, whereas there was more PD controls than PD patients in the lower tertile (P = 0.006). Median serum levels of HO-1 did not differ significantly between AD patients and AD controls. CONCLUSION: The increase of serum HO-1 levels in PD patients could indicate a systemic antioxidant reaction related to a chronic oxidative stress state in PD brain.
Subject(s)
Alzheimer Disease/blood , Heme Oxygenase-1/blood , Parkinson Disease/blood , Adult , Age Factors , Aged , Aged, 80 and over , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Apolipoprotein E4/genetics , Female , Humans , Male , Middle Aged , Parkinson Disease/drug therapy , Severity of Illness Index , Sex Factors , Time FactorsABSTRACT
OBJECTIVE: Glycogen synthase kinase-3beta (GSK-3beta) and cyclin-dependent kinase 5 (CDK5) have been implicated as two major protein kinases involved in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles. CDK5 regulatory subunit 1 (CDK5R1) encodes for p35, a protein required for activation of CDK5. As both CDK5R1 and GSK-3beta genes are related to phosphorylation of tau, we examined the combined contribution of these genes to the susceptibility for AD. METHODS: In a case-control study in 283 AD patients and 263 healthy controls, we examined the combined effects between CDK5R1 (3'-UTR, rs735555) and GSK-3beta (-50, rs334558) polymorphisms on susceptibility to AD. RESULTS: Subjects carrying both the CDK5R1 (3'-UTR, rs735555) AA genotype and the GSK-3beta (-50, rs334558) CC genotype had a 12.5-fold decrease in AD risk (adjusted by age, sex and APOE status OR = 0.08, 95% CI = 0.01-0.76, P = 0.03), suggesting synergistic effects (epistasis) between both genes. CONCLUSION: These data support a role for tau phosphorylation regulating genes in risk for AD.
Subject(s)
Alzheimer Disease/genetics , Cyclin-Dependent Kinase 5/genetics , Epistasis, Genetic , Glycogen Synthase Kinase 3/genetics , Protein Subunits/genetics , Aged , Aged, 80 and over , Alzheimer Disease/etiology , Case-Control Studies , Female , Glycogen Synthase Kinase 3 beta , Humans , Male , Middle Aged , Phosphorylation/genetics , Risk Factors , tau Proteins/geneticsABSTRACT
OBJECTIVE: To describe the case of a young woman with the diagnosis of acute inflammatory demyelinating polyradiculoneuropathy (AIDP), who during the course of the disease developed an electrophysiologic pattern of acute motor conduction block neuropathy (AMCBN). METHODS: Electrophysiologic techniques including needle EMG, standard motor and sensory nerve conductions studies, and somatosensory evoked potentials were carried out over the four months after symptom onset. RESULTS: The results of four neurophysiological studies, performed on Days 14, 26, 35 and 125 after symptomatic onset are reported. All immunological determinations including antiganglioside antibodies (GM1, GM2, GM3, asialoGM1, GD1a, GD1b, GD3, GQ1b and GT1b) were negative. The patient had a favorable evolution following treatment with intravenous immunoglobulins (IVIg). CONCLUSIONS: We conclude that the electrophysiologic hallmark of AMCBN may occur in the course of AIDP. Serial investigation including proximal, intermediate and distal segments of all nerves from upper and lower limbs is essential for its detection.
Subject(s)
Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/physiopathology , Motor Neurons/physiology , Neural Conduction/physiology , Adult , Electrodiagnosis , Electromyography , Electrophysiology , Evoked Potentials, Somatosensory/physiology , Female , Functional Laterality/physiology , Humans , Median Nerve/physiopathology , Muscle, Skeletal/physiology , Neurologic Examination , Peroneal Nerve/physiopathology , Tibial Nerve/physiopathologyABSTRACT
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, IL-1alpha and IL-10] involved in the brain neuroinflammatory pathway in Parkinson's disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain. Set-association analysis did not reveal an independent or an interactive effect of these inflammatory genes on the PD risk.